PERSONAL INFORMATION
Name: JIANG NING
Birth Date: August 12,1989
Tel: 13648393869
E-mail: jiangning@cqmu.edu.cn
EDUCATION EXPERIENCE
2008.09-2013.06 Chongqing Medical University Clinical Medicine (Bachelor)
2013.09-2016.06 Chongqing Medical University Clinical Medicine (Master)
2016.09-2019.06 Chongqing Medical University Basic medicine (Doctor)
WORKING EXPERIENCE
2019.09-2021.11 Department of Pathology, Chongqing Medical University Doctor ＆ Lecture
2021.12-now Department of Pathology, Chongqing Medical University Associate professor
RESEARCH INTERESTS
1. Starting from clinical tumor patient samples, focus on the development and application of bioinformatics sequencing technology, covering high-throughput functional genomics, proteomics and metabolomics of coding and non-coding sequences, in order to mine effective clinical diagnostic and prognostic markers;
2. Focus on the molecular mechanism of hepatobiliary and pancreatic tumor occurrence and development, and explore the possible regulatory mechanism in the process of tumor occurrence and development through sequencing results and conduct basic experimental verification, so as to provide drug targets and ideas for the development of new therapies;
3. New tumor photothermal/photodynamic therapy of functional endogenous substances, targeted drug delivery and treatment of tumor by functional biological nanoparticles, and drug resistance evaluation of targeted tumor therapy by electrochemistry and spectroscopy were carried out to provide reliable basic technical support for clinical application.
FOUNDATIONS
1. National Natural Science Foundation of China (No. 82203310) ，2023.1-2025.12 ，Host；
2. Natural Science Foundation of Chongqing (No.cstc2020jcyj-msxmX0144) ，2020.10-2023.6 ，Host；
3. Science and Technology Research program of chongqing Education Commission (No.KJQN202000401)， 2020.9-2023.10 ，Host；
4. The first Excellent Young Talents Program of Basic Medical College of Chongqing Medical University， 2020.1-2022.12 ，Host；
5. Key project of Chongqing Natural Science Foundation (No. cstc2017jcyjB0283), 2017.9-2020.9 ，Participate.
PUBLICATIONS
1. Necroptosis-Related Prognostic Model for Pancreatic Carcinoma Reveals Its Invasion and Metastasis Potential through Hybrid EMT and Immune Escape. Biomedicines. 2023 Jun 16;11(6):1738. (co-corresponding author, IF: 4.7）
2. Aptamere-Engineered Polydopamine Nanospheres for Target Delivery and Tumor Perfusion in Synergistic Chemo- Phototpy of Pancreatic Cancer[J]. ACS Applied Materials & Interfaces, 2023,
15(13): 16539-16551.(co-corresponding author, IF: 10.5）
3. A “nano-courier” for Precise Delivery of Acetylcholine and Melatonin by C5a-targeted Aptamers Effectively
Attenuates Reperfusion Injury of Ischemic Stroke[J]. Advanced Functional Materials, 2023.（co-corresponding author, IF: 19.92）
4. Intelligent recognition of CTCs from gallbladder cancer by ultrasensitive electrochemical cytosensorand diagnosis of chemotherapeutic resistance[J]. Biosensors and Bioelectronics, 2023: 115183.（cocorresponding author, IF: 12.55）
5. Emerging chemical engineering of exosomes as" bioscaffolds" in diagnostics and therapeutics[J]. Genes & Diseases, 2022.（co-corresponding author, IF：7.243）
6. E3 Ubiquitin Ligase FBXO3 Drives Neuroinflammation to Aggravate Cerebral
Ischemia/Reperfusion Injury. Int J Mol Sci. 2022 Nov 7;23(21):13648.（co-corresponding author, IF: 6.208）
7. NLRP6 dependent pyroptosis-related lncRNAs predict the prognosis of hepatocellular carcinoma. Frontiers in Medicine. (co-corresponding author, IF：5.06)
8. H/ACA snoRNP Gene Family as Diagnostic and Prognostic Biomarkers for Hepatocellular Carcinoma[J]. Pharmacogenomics and Personalized Medicine, 2021, 14: 1331. (co-corresponding author, IF: 3.912)
9. AGTRAP Is a Prognostic Biomarker Correlated With Immune Infiltration in Hepatocellular Carcinoma.Front Oncol.
2021 Sep 14;11:713017. (co-corresponding author, IF: 6.244)
10. 6-Gingerol protects against cerebral ischemia/reperfusion injury by inhibiting NLRP3 inflammasome and apoptosis via TRPV1 / FAF1 complex dissociation-mediated autophagy. Int Immunopharmacol. 2021 Nov;100:108146.(co-corresponding author, IF: 5.71)
11. Mining of RNA Methylation-Related Genes and Elucidation of Their Molecular Biology in Gallbladder Carcinoma. Front Oncol . 2021 Feb 25;11:621806. (co-corresponding author, IF: 6.244)
12. LETM1 Knockdown Promotes Autophagy and Apoptosis Through AMP-Activated Protein Kinase Phosphorylation-Mediated Beclin-1/Bcl-2 Complex Dissociation in Hepatocellular Carcinoma. Front Oncol. 2021 Jan 21;10:606790. (co-corresponding author, IF: 6.244)
13. The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review. [J].Pathog Dis , 2020,
78: undefined. (Corresponding author, IF: 3.166)
14. Dishevelled-1 regulated apoptosis through NF-κB in cerebral ischemia/reperfusion injury in rats.[J]. Neurosci. Lett., 2020, 722: 134862. (Corresponding author, IF: 3.046)
15. NLRP6 expressed in astrocytes aggravates neurons injury after OGD/R through activating the inflammasome and inducing pyroptosis.[J]. Int Immunopharmacol, 2020, 80: 106183. (Co-first author, IF: 4.932)
16. TOM7 silencing exacerbates focal cerebral ischemia injury in rat by targeting PINK1/Beclin1-mediated
autophagy.[J].Behav. Brain Res , 2019, 360: 113-119. (First author, IF: 2.977)
17. Systemic and intratumoral balances between monocytes/ macrophages and lymphocytes predict prognosis in hepatocellular carcinoma patients after surgery[J]. Oncotarget, 2016 May 24; 7(21): 30951–30961. (Co- first author, IF: 5.168)
18. TAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinoma. Cancer Sci. 2015 Feb;106(2):151-9. (Co- first author, IF: 3.9)
